RCT in Nature Medicine; renewed interest in digoxin.
Low-dose digoxin did not significantly reduce the composite endpoint of total worsening heart failure events or cardiovascular mortality compared to placebo (Rate ratio 0.81).
RCT
1:1
Double-blind
Yes
Heart failure with reduced or mildly reduced ejection fraction (n=1,001)
Digoxin vs Placebo (0.1 mg or 0.2 mg once daily (target serum concentration 0.5-0.9 ng/ml))
Composite of total worsening heart failure events (total hospitalizations or urgent visits) and cardiovascular mortality — Rate ratio 0.81 (0.61-1.07), p=0.133
“the results will determine whether the reevaluation applies to all members of this therapeutic class or only to digitoxin”
Building similarity graph...
Analyzing shared references across papers
Loading...
D. J. van Veldhuisen
M. Rienstra
A. Mosterd
Nature Medicine
Building similarity graph...
Analyzing shared references across papers
Loading...
Veldhuisen et al. (Sun,) conducted a rct in Heart failure with reduced or mildly reduced ejection fraction (n=1,001). Digoxin vs. Placebo was evaluated on Composite of total worsening heart failure events (total hospitalizations or urgent visits) and cardiovascular mortality (Rate ratio 0.81, 95% CI 0.61-1.07, p=0.133). Low-dose digoxin did not significantly reduce the composite endpoint of total worsening heart failure events or cardiovascular mortality compared to placebo (Rate ratio 0.81).
www.synapsesocial.com/papers/6a019f1ac802e0b13c07fa74 — DOI: https://doi.org/10.1038/s41591-026-04406-6
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: